Alnylam Pharmace. buy StockNews.com
Start price
27.12.24
/
50%
€230.70
Target price
27.12.25
-
Performance (%)
46.25%
End price
28.12.25
€337.40
Summary
This prediction ended on 28.12.25 with a price of €337.40. With a performance of 46.25% the BUY prediction by StockNews_com was a big success. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 0.322% | 0.322% | 46.827% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten